- Home
- PBT vs ALMS Comparison
PBT vs ALMS Comparison
Compare PBT & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBT
- ALMS
- Stock Information
- Founded
- PBT 1980
- ALMS 2021
- Country
- PBT United States
- ALMS United States
- Employees
- PBT N/A
- ALMS N/A
- Industry
- PBT Oil & Gas Production
- ALMS
- Sector
- PBT Energy
- ALMS
- Exchange
- PBT Nasdaq
- ALMS NYSE
- Market Cap
- PBT 475.4M
- ALMS 402.6M
- IPO Year
- PBT N/A
- ALMS 2024
- Fundamental
- Price
- PBT $10.52
- ALMS $4.46
- Analyst Decision
- PBT
- ALMS Strong Buy
- Analyst Count
- PBT 0
- ALMS 7
- Target Price
- PBT N/A
- ALMS $28.00
- AVG Volume (30 Days)
- PBT 81.2K
- ALMS 410.3K
- Earning Date
- PBT 01-01-0001
- ALMS 05-19-2025
- Dividend Yield
- PBT 3.94%
- ALMS N/A
- EPS Growth
- PBT N/A
- ALMS N/A
- EPS
- PBT 0.55
- ALMS N/A
- Revenue
- PBT $27,114,144.00
- ALMS N/A
- Revenue This Year
- PBT N/A
- ALMS N/A
- Revenue Next Year
- PBT N/A
- ALMS N/A
- P/E Ratio
- PBT $18.56
- ALMS N/A
- Revenue Growth
- PBT N/A
- ALMS N/A
- 52 Week Low
- PBT $8.01
- ALMS $3.18
- 52 Week High
- PBT $14.26
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- PBT 62.56
- ALMS N/A
- Support Level
- PBT $9.73
- ALMS N/A
- Resistance Level
- PBT $10.20
- ALMS N/A
- Average True Range (ATR)
- PBT 0.34
- ALMS 0.00
- MACD
- PBT 0.07
- ALMS 0.00
- Stochastic Oscillator
- PBT 97.37
- ALMS 0.00
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.